Drug Patents owned by Nextwave

1. Drug name - QUILLIVANT XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 NEXTWAVE Modified release formulations containing drug-ion exchange resin complexes Mar, 2029

(6 years from now)

US8778390 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8956649 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8465765 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US9040083 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8287903 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8563033 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.